NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual…more
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual…more
Analyst consensus: Buy
As of 22 Jul 2026, 5 analysts rate NIOX Group Plc a Buy, with 100% buy ratings and a mean price target of 81p (range 77p–86p), +33% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 46p against a current price of 62p (-26%), based on EV/EBITDA.